Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment
01 nov. 2021 08h00 HE
|
Cocrystal Pharma, Inc.
FDA’s response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 clinical trials for CDI-45205 BOTHELL, Wash., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cocrystal...